Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Whether transcatheter aortic-valve replacement can improve outcomes in patients with asymptomatic severe aortic stenosis has been unclear. New research findings comparing TAVR with clinical ...

Edwards Lifesciences (NYSE:EW) traded higher on Thursday after Stifel upgraded the heart device maker to Buy from Hold, citing a turnaround in its position in the market for transcatheter aortic valve ...

Transcatheter aortic valve replacement (TAVR) is valve replacement without open-heart surgery. It is also called catheter-based or percutaneous (through the skin) aortic valve replacement. While ...

You’re just not pumping efficiently enough,” said Roger Janes, 1500th successful TAVR patient from Meadville. Janes added he’ll have to exercise 30 minutes a day for five days a week.

Since initial FDA approval in 2011, TAVR has revolutionized ... faculty who come together and review all data to bring about the best outcome in each and every patient,” says Olcay Aksoy ...

With its potential to improve clinical outcomes for a broader range of patients, the JenaValve Trilogy System underscores the growing adaptability of TAVR technology in treating complex heart ...